These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 38298504)

  • 21. Recent advances in the management of pulmonary hypertension with interstitial lung disease.
    Waxman AB; Elia D; Adir Y; Humbert M; Harari S
    Eur Respir Rev; 2022 Sep; 31(165):. PubMed ID: 35831007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Screening Strategies for Pulmonary Hypertension in Patients With Interstitial Lung Disease: A Multidisciplinary Delphi Study.
    Rahaghi FF; Kolaitis NA; Adegunsoye A; de Andrade JA; Flaherty KR; Lancaster LH; Lee JS; Levine DJ; Preston IR; Safdar Z; Saggar R; Sahay S; Scholand MB; Shlobin OA; Zisman DA; Nathan SD
    Chest; 2022 Jul; 162(1):145-155. PubMed ID: 35176276
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unmasking a Silent Threat: Improving Pulmonary Hypertension Screening Methods for Interstitial Lung Disease Patients.
    Averjanovaitė V; Gumbienė L; Zeleckienė I; Šileikienė V
    Medicina (Kaunas); 2023 Dec; 60(1):. PubMed ID: 38256318
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease.
    Launay D; Humbert M; Berezne A; Cottin V; Allanore Y; Couderc LJ; Bletry O; Yaici A; Hatron PY; Mouthon L; Le Pavec J; Clerson P; Hachulla E
    Chest; 2011 Oct; 140(4):1016-1024. PubMed ID: 21474572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pulmonary Hypertension in the Course of Interstitial Lung Diseases-A Personalised Approach Is Needed to Identify a Dominant Cause and Provide an Effective Therapy.
    Kacprzak A; Tomkowski W; Szturmowicz M
    Diagnostics (Basel); 2023 Jul; 13(14):. PubMed ID: 37510098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD).
    Copeland CR; Lancaster LH
    Front Med (Lausanne); 2021; 8():743977. PubMed ID: 34722582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic use of PAH-specific therapy in World Health Organization Group III Pulmonary Hypertension: a systematic review and meta-analysis.
    Prins KW; Duval S; Markowitz J; Pritzker M; Thenappan T
    Pulm Circ; 2017 Mar; 7(1):145-155. PubMed ID: 28680574
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pulmonary hypertension in chronic obstructive and interstitial lung diseases.
    Andersen CU; Mellemkjær S; Nielsen-Kudsk JE; Bendstrup E; Hilberg O; Simonsen U
    Int J Cardiol; 2013 Oct; 168(3):1795-804. PubMed ID: 23849967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The PH-ILD Detection tool: External validation and use in patients with ILD.
    Parikh R; O'Sullivan DM; Farber HW
    Pulm Circ; 2023 Jul; 13(3):e12273. PubMed ID: 37564922
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pulmonary hypertension in the setting of interstitial lung disease: Approach to management and treatment. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative-Group 3 Pulmonary Hypertension.
    Shlobin OA; Shen E; Wort SJ; Piccari L; Scandurra JA; Hassoun PM; Nikkho SM; Nathan SD
    Pulm Circ; 2024 Jan; 14(1):e12310. PubMed ID: 38205098
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of interstitial lung disease associated with connective tissue disease.
    Mathai SC; Danoff SK
    BMJ; 2016 Feb; 352():h6819. PubMed ID: 26912511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Challenge of Diagnosing and Managing Pulmonary Arterial Hypertension in Systemic Sclerosis with Interstitial Lung Disease.
    Zanatta E; Marra MP; Famoso G; Balestro E; Giraudo C; Calabrese F; Rea F; Doria A
    Pharmaceuticals (Basel); 2022 Aug; 15(9):. PubMed ID: 36145263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of post-capillary pulmonary hypertension on mortality in interstitial lung disease.
    Teramachi R; Taniguchi H; Kondoh Y; Kimura T; Kataoka K; Yokoyama T; Furukawa T; Yagi M; Sakamoto K; Hashimoto N; Hasegawa Y
    Respir Investig; 2021 May; 59(3):342-349. PubMed ID: 33579646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pulmonary hypertension in patients with interstitial lung disease.
    Karampitsakos T; Tzouvelekis A; Chrysikos S; Bouros D; Tsangaris I; Fares WH
    Pulm Pharmacol Ther; 2018 Jun; 50():38-46. PubMed ID: 29605286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety, Tolerability, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder for Pulmonary Hypertension: A Phase 1, Randomized, Double-Blind, Single- and Multiple-Dose Study.
    Ismat FA; Usansky HH; Villa R; Zou J; Teper A
    Adv Ther; 2022 Nov; 39(11):5144-5157. PubMed ID: 36070132
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical characteristics and outcomes in pulmonary manifestations of systemic sclerosis: Contribution from pulmonary hypertension and interstitial lung disease severity.
    Sangani RA; Lui JK; Gillmeyer KR; Trojanowski MA; Bujor AM; LaValley MP; Klings ES
    Pulm Circ; 2022 Oct; 12(4):e12117. PubMed ID: 36238967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mortality and hospitalization outcomes of interstitial lung disease and pulmonary hypertension in the Singapore systemic sclerosis cohort.
    Noviani M; Saffari SE; Tan JL; Yip JWL; Teng GG; Law WG; Chan GYL; Santosa A; Lim AYN; Hong C; Ng SA; Tay ELW; Ruan W; Yap J; Low AHL
    Semin Arthritis Rheum; 2020 Jun; 50(3):473-479. PubMed ID: 31810742
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension and interstitial lung disease.
    Volkmann ER; Saggar R; Khanna D; Torres B; Flora A; Yoder L; Clements PJ; Elashoff RM; Ross DJ; Agrawal H; Borazan N; Furst DE; Saggar R
    Arthritis Rheumatol; 2014 Jul; 66(7):1900-8. PubMed ID: 24729406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Severe pulmonary hypertension-interstitial lung disease presenting as right ventricular failure: stabilisation with intravenous prostacyclin and maintenance with inhaled prostacyclin.
    Parikh R; Thomas A; Sharofi A; Moallem N; Fiscus G; Farber HW
    ERJ Open Res; 2024 Jan; 10(1):. PubMed ID: 38288084
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of High-Resolution CT Thorax in Diagnosing Interstitial Lung Disease and Its Association With Smoking and Connective Tissue Disorder.
    Doshi JA; Mundhra KS; Shah DS; Shah SN; Patel TV; Bhatt A
    Cureus; 2022 Nov; 14(11):e31107. PubMed ID: 36475156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.